Edwards  ||| S:0 E:8 ||| NNP
CENTERA  ||| S:8 E:16 ||| NNP
valve  ||| S:16 E:22 ||| FW
Transcatheter  ||| S:22 E:36 ||| FW
aortic  ||| S:36 E:43 ||| FW
valve  ||| S:43 E:49 ||| FW
implantation  ||| S:49 E:62 ||| FW
( ||| S:62 E:63 ||| -LRB-
TAVI ||| S:63 E:67 ||| NNP
)  ||| S:67 E:69 ||| -RRB-
has  ||| S:69 E:73 ||| VBZ
been  ||| S:73 E:78 ||| VBN
adopted  ||| S:78 E:86 ||| VBN
worldwide  ||| S:86 E:96 ||| VBN
as  ||| S:96 E:99 ||| IN
a  ||| S:99 E:101 ||| DT
prominent  ||| S:101 E:111 ||| JJ
therapeutic  ||| S:111 E:123 ||| JJ
alternative  ||| S:123 E:135 ||| NN
for  ||| S:135 E:139 ||| IN
patients  ||| S:139 E:148 ||| NNS
with  ||| S:148 E:153 ||| IN
high-risk  ||| S:153 E:163 ||| JJ
severe  ||| S:163 E:170 ||| JJ
symptomatic  ||| S:170 E:182 ||| JJ
aortic  ||| S:182 E:189 ||| JJ
stenosis ||| S:189 E:197 ||| NN
.  ||| S:197 E:199 ||| .
Despite  ||| S:199 E:207 ||| IN
its  ||| S:207 E:211 ||| PRP$
more  ||| S:211 E:216 ||| JJR
widespread  ||| S:216 E:227 ||| JJ
adoption  ||| S:227 E:236 ||| NN
as  ||| S:236 E:239 ||| IN
a  ||| S:239 E:241 ||| DT
treatment  ||| S:241 E:251 ||| NN
option  ||| S:251 E:258 ||| NN
and  ||| S:258 E:262 ||| CC
the  ||| S:262 E:266 ||| DT
increasing  ||| S:266 E:277 ||| JJ
experience  ||| S:277 E:288 ||| NN
of  ||| S:288 E:291 ||| IN
the  ||| S:291 E:295 ||| DT
centres ||| S:295 E:302 ||| NN
,  ||| S:302 E:304 ||| ,
TAVI  ||| S:304 E:309 ||| NNP
is  ||| S:309 E:312 ||| VBZ
still  ||| S:312 E:318 ||| RB
associated  ||| S:318 E:329 ||| VBN
with  ||| S:329 E:334 ||| IN
complications ||| S:334 E:347 ||| NNS
.  ||| S:347 E:349 ||| .
Therefore ||| S:349 E:358 ||| RB
,  ||| S:358 E:360 ||| ,
improvements  ||| S:360 E:373 ||| NNS
in  ||| S:373 E:376 ||| IN
transcatheter  ||| S:376 E:390 ||| JJ
heart  ||| S:390 E:396 ||| NN
valve  ||| S:396 E:402 ||| NNS
( ||| S:402 E:403 ||| -LRB-
THV ||| S:403 E:406 ||| NNP
)  ||| S:406 E:408 ||| -RRB-
technology ||| S:408 E:418 ||| NN
,  ||| S:418 E:420 ||| ,
such  ||| S:420 E:425 ||| JJ
as  ||| S:425 E:428 ||| IN
optimisation  ||| S:428 E:441 ||| NN
of  ||| S:441 E:444 ||| IN
device  ||| S:444 E:451 ||| NN
function  ||| S:451 E:460 ||| NN
with  ||| S:460 E:465 ||| IN
superior  ||| S:465 E:474 ||| JJ
deliverability ||| S:474 E:488 ||| NN
,  ||| S:488 E:490 ||| ,
and  ||| S:490 E:494 ||| CC
valve  ||| S:494 E:500 ||| JJ
repositioning ||| S:500 E:513 ||| NN
,  ||| S:513 E:515 ||| ,
are  ||| S:515 E:519 ||| VBP
desirable ||| S:519 E:528 ||| JJ
.  ||| S:528 E:530 ||| .
Accordingly ||| S:530 E:541 ||| RB
,  ||| S:541 E:543 ||| ,
this  ||| S:543 E:548 ||| DT
article  ||| S:548 E:556 ||| NN
describes  ||| S:556 E:566 ||| VBZ
the  ||| S:566 E:570 ||| DT
new  ||| S:570 E:574 ||| JJ
self-expandable  ||| S:574 E:590 ||| JJ
Edwards  ||| S:590 E:598 ||| NNP
CENTERA  ||| S:598 E:606 ||| NNP
THV ||| S:606 E:609 ||| NNP
,  ||| S:609 E:611 ||| ,
made  ||| S:611 E:616 ||| VBN
of  ||| S:616 E:619 ||| IN
nitinol  ||| S:619 E:627 ||| NN
and  ||| S:627 E:631 ||| CC
treated  ||| S:631 E:639 ||| VBN
bovine  ||| S:639 E:646 ||| JJ
pericardial  ||| S:646 E:658 ||| JJ
tissue ||| S:658 E:664 ||| NN
,  ||| S:664 E:666 ||| ,
and  ||| S:666 E:670 ||| CC
delivered  ||| S:670 E:680 ||| VBN
by  ||| S:680 E:683 ||| IN
a  ||| S:683 E:685 ||| DT
motorised  ||| S:685 E:695 ||| JJ
low-profile  ||| S:695 E:707 ||| JJ
delivery  ||| S:707 E:716 ||| NN
system  ||| S:716 E:723 ||| NN
which  ||| S:723 E:729 ||| WDT
potentially  ||| S:729 E:741 ||| RB
permits  ||| S:741 E:749 ||| VBZ
accurate  ||| S:749 E:758 ||| JJ
valve  ||| S:758 E:764 ||| JJ
placement  ||| S:764 E:774 ||| NN
and  ||| S:774 E:778 ||| CC
valve  ||| S:778 E:784 ||| JJ
repositioning  ||| S:784 E:798 ||| NN
by  ||| S:798 E:801 ||| IN
a  ||| S:801 E:803 ||| DT
single  ||| S:803 E:810 ||| JJ
operator ||| S:810 E:818 ||| NN
.  ||| S:818 E:820 ||| .
First-in-human  ||| S:820 E:835 ||| JJ
clinical  ||| S:835 E:844 ||| JJ
experience  ||| S:844 E:855 ||| NN
with  ||| S:855 E:860 ||| IN
the  ||| S:860 E:864 ||| DT
CENTERA  ||| S:864 E:872 ||| NNP
THV  ||| S:872 E:876 ||| NNP
has  ||| S:876 E:880 ||| VBZ
been  ||| S:880 E:885 ||| VBN
promising  ||| S:885 E:895 ||| JJ
but  ||| S:895 E:899 ||| CC
larger  ||| S:899 E:906 ||| JJR
series  ||| S:906 E:913 ||| NN
with  ||| S:913 E:918 ||| IN
longer  ||| S:918 E:925 ||| JJR
follow-up  ||| S:925 E:935 ||| NNS
are  ||| S:935 E:939 ||| VBP
warranted  ||| S:939 E:949 ||| VBN
to  ||| S:949 E:952 ||| TO
confirm  ||| S:952 E:960 ||| VB
these  ||| S:960 E:966 ||| DT
initial  ||| S:966 E:974 ||| JJ
positive  ||| S:974 E:983 ||| JJ
results ||| S:983 E:990 ||| NNS
.  ||| S:990 E:992 ||| .
